These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21963936)

  • 1. Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
    Lichterfeld M; Gandhi RT; Simmons RP; Flynn T; Sbrolla A; Yu XG; Basgoz N; Mui S; Williams K; Streeck H; Burgett-Yandow N; Roy G; Janssens M; Pedneault L; Vandepapelière P; Koutsoukos M; Demoitié MA; Bourguignon P; McNally L; Voss G; Altfeld M
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):1-9. PubMed ID: 21963936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
    Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
    Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.
    Jost S; Tomezsko PJ; Rands K; Toth I; Lichterfeld M; Gandhi RT; Altfeld M
    J Virol; 2014 Aug; 88(15):8349-54. PubMed ID: 24829350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
    Garrett N; Dintwe O; Monaco CL; Jones M; Seaton KE; Church EC; Grunenberg N; Hutter J; deCamp A; Huang Y; Lu H; Mann P; Robinson ST; Heptinstall J; Jensen RL; Pantaleo G; Ding S; Koutsoukos M; Hosseinipour MC; Van Der Meeren O; Gilbert PB; Ferrari G; Andersen-Nissen E; McElrath MJ; Tomaras GD; Gray GE; Corey L; Kublin JG;
    J Acquir Immune Defic Syndr; 2024 Aug; 96(4):350-360. PubMed ID: 38916429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
    Van Braeckel E; Bourguignon P; Koutsoukos M; Clement F; Janssens M; Carletti I; Collard A; Demoitié MA; Voss G; Leroux-Roels G; McNally L
    Clin Infect Dis; 2011 Feb; 52(4):522-31. PubMed ID: 21208909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01
    Van Der Meeren O; Jongert E; Seaton KE; Koutsoukos M; Aerssens A; Brackett C; Debois M; Janssens M; Leroux-Roels G; Mesia Vela D; Sawant S; Yates NL; Tomaras GD; Leroux-Roels I; Roman F
    Vaccine; 2020 Feb; 38(7):1678-1689. PubMed ID: 31932137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial.
    Chua JV; Davis C; Husson JS; Nelson A; Prado I; Flinko R; Lam KWJ; Mutumbi L; Mayer BT; Dong D; Fulp W; Mahoney C; Gerber M; Gottardo R; Gilliam BL; Greene K; Gao H; Yates N; Ferrari G; Tomaras G; Montefiori D; Schwartz JA; Fouts T; DeVico AL; Lewis GK; Gallo RC; Sajadi MM
    Vaccine; 2021 Jun; 39(29):3879-3891. PubMed ID: 34099328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
    Leroux-Roels G; Bourguignon P; Willekens J; Janssens M; Clement F; Didierlaurent AM; Fissette L; Roman F; Boutriau D
    Clin Vaccine Immunol; 2014 Mar; 21(3):302-11. PubMed ID: 24391139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.